Ser695
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.5
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser695  -  PKDREJ (human)

Site Information
VGPSsLLstLIQKKD   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 17399772

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 )
Disease tissue studied:
liver cancer ( 2 ) , hepatocellular carcinoma ( 2 )
Relevant cell line - cell type - tissue:
HeLa (cervical) ( 1 ) , hepatocyte-liver ( 2 )

References 

1

Zhou J (2010) CST Curation Set: 10712; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-PLK Binding Motif (ST*P) (D73F6) Rabbit mAb Cat#: 5243, PTMScan(R) Phospho-PLK Binding Motif (ST*P) Immunoaffinity Beads Cat#: 5756
Curated Info

2

Gu T (2009) CST Curation Set: 7528; Year: 2009; Biosample/Treatment: liver, hepatocyte/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info